Non-traditional risk factors for atherosclerosis

被引:0
作者
Acevedo, M
Tagle, R
Simpfendorfer, C
机构
[1] Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA
关键词
atherosclerosis; C-reactive protein; fibrinogen; homocysteine; lipoprotein (a); risk factors;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the last 10 year, several "non-traditional" risk markers for, atherosclerosis haze been identified. Among them, new markers of lipoprotein metabolism (ie lipoprotein [a]), endothelial dysfunction (ie homocysteine), hemostasis (ie fibrinogen) crud inflammation (ie C-reactive protein) hate beers linked to an excessive risk of cardiovascular disease. These factors should help the clinician to better identify individuals at risk of premature atherosclerotic disease and/or improve the predictive value of established risk factors for atherosclerosis. Finally, these factors are expected to improve the knowledge in the pathophysiology of cardiovascular diseases, crud perhaps to impact future therapeutic decisions. In this review article, the will analyze the markers its which there are at least some evidence to support their acceptance as "non-traditional risk. factors" for atherosclerotic disease.
引用
收藏
页码:1212 / 1221
页数:10
相关论文
共 60 条
[41]   Task force 3. Spectrum of risk factors for coronary heart disease [J].
Pasternak, RC ;
Grundy, SM ;
Levy, D ;
Thompson, PD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (05) :978-990
[42]  
Ridker PM, 2001, CIRCULATION, V103, P1191
[43]  
Ridker PM, 1998, CIRCULATION, V97, P425
[44]   High-sensitivity C-reactive protein - Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease [J].
Ridker, PM .
CIRCULATION, 2001, 103 (13) :1813-1818
[45]   A PROSPECTIVE-STUDY OF LIPOPROTEIN(A) AND THE RISK OF MYOCARDIAL-INFARCTION [J].
RIDKER, PM ;
HENNEKENS, CH ;
STAMPFER, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (18) :2195-2199
[46]   Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels [J].
Ridker, PM ;
Rifai, N ;
Pfeffer, MA ;
Sacks, FM ;
Moye, LA ;
Goldman, S ;
Flaker, GC ;
Braunwald, E .
CIRCULATION, 1998, 98 (09) :839-844
[47]   Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events [J].
Ridker, PM ;
Rifai, N ;
Clearfield, M ;
Downs, JR ;
Weis, SE ;
Miles, JS ;
Gotto, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (26) :1959-1965
[48]   Long-term effects of pravastatin on plasma concentration of C-reactive protein [J].
Ridker, PM ;
Rifai, N ;
Pfeffer, MA ;
Sacks, F ;
Braunwald, E .
CIRCULATION, 1999, 100 (03) :230-235
[49]   Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [J].
Ridker, PM ;
Cushman, M ;
Stampfer, MJ ;
Tracy, RP ;
Hennekens, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (14) :973-979
[50]   C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women [J].
Ridker, PM ;
Hennekens, CH ;
Buring, JE ;
Rifai, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (12) :836-843